Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study

Background/Aims Biologics are increasingly used to manage ulcerative colitis (UC) and Crohn’s disease (CD). However, even with earlier usage of biologic therapy, a significant proportion of patients will require surgery. Vedolizumab is an anti-integrin antibody that is increasingly used given that i...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs: Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Formaat: Artikel
Taal:English
Gepubliceerd in: Korean Association for the Study of Intestinal Diseases 2022-01-01
Reeks:Intestinal Research
Onderwerpen:
vedolizumab
ulcerative colitis
surgical complications
crohn disease
inflammatory bowel disease
Online toegang:http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Internet

http://irjournal.org/upload/pdf/ir-2020-00117.pdf

Gelijkaardige items